Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus
Conditions: Kidney Transplant; Complications; Diabetes Mellitus Interventions: Drug: Empagliflozin 25 MG; Drug: Linagliptin Sponsors: Medanta, The Medicity, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
Conditions: Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus, Type 2; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; CKD; CKD Stage 3; CKD Stage 4 Interventions: Drug: Empagliflozin 10 MG; Drug: Finerenone; Device: Withings BPM Connect; Device: Withings Body; Diagnostic Test: PeeSpot Urine Collection Device; Diagnostic Test: Hem-Col Capillary Blood Collection Device; Behavioral: Questionnaire: participants ' perspectives toward the feasibility of parti...
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
Conditions: Diabetes Mellitus, Type 2 Interventions: Drug: Semaglutide; Drug: Empagliflozin; Drug: Metformin Sponsors: Novo Nordisk A/S Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: a study protocol for a randomized, double-blinded, three-arm parallel-group, controlled trial
DiscussionThe present study will be the first trial to evaluate the efficacy and safety of early treatment with the combination of standard-dose empagliflozin and colchicine as well as high-dose empagliflozin in non-diabetic patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction. The results of this research will represent a significant step forward in the treatment of patients with acute myocardial infarction.Trial registrationClinical trial ID: IRCT20111206008307N39. Registration date: 27 October 2022.Graphical Abstract (Source: Trials)
Source: Trials - October 6, 2023 Category: Research Source Type: clinical trials
Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients
Conditions: Heart Failure; Reduced Ejection Fraction Heart Failure Interventions: Drug: Empagliflozin 10 MG; Drug: Dapagliflozin 10 MG Sponsors: Damanhour University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
The Effects and Mechanism of SGLT2 Inhibitors in Stage B of Heart Failure With Hypertension
Conditions: Heart Failure; Hypertension; Left Ventricle Remodeling; Left Atrial Dilatation Interventions: Drug: Empagliflozin 10 MG; Drug: Placebo Sponsors: China National Center for Cardiovascular Diseases Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
Conditions: Heart Failure With Preserved Ejection Fraction; Microvascular Dysfunction Intervention: Drug: Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment Sponsor: Maastricht University Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
Conditions: Heart Failure With Preserved Ejection Fraction; Microvascular Dysfunction Interventions: Drug: Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment Sponsors: Maastricht University Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
